Trials / Completed
CompletedNCT00345501
Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention
Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients With Preexisting Renal Dysfunction Undergoing a Coronary Procedure
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 208 (actual)
- Sponsor
- Onassis Cardiac Surgery Centre · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The prevention of contrast-mediated nephropathy (CMN), which accounts for considerable morbidity and mortality, remains a vexing problem. Contrast induced renal vasoconstriction is believed to play a pivotal role in the CMN mechanism. The aim of this study is to examine the efficacy of the prostacyclin analogue iloprost (dose 1ng/kg/min) in preventing CMN in high-risk patients undergoing a coronary procedure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iloprost | Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end |
| DRUG | Placebo | Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end |
Timeline
- Start date
- 2005-11-01
- Completion
- 2007-07-01
- First posted
- 2006-06-28
- Last updated
- 2007-08-24
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT00345501. Inclusion in this directory is not an endorsement.